First European Marketing Authorisation application

Vetbiobank reaches another major Milestone with the Successful Submission of its Centralised Marketing Authorisation Application for Its “Best in Class” Canine Neonatal Stem Cells product for treating Canine Osteoarthritis ! 

We are thrilled to announce that thanks to the exceptional dedication of our teams at Vetbiobank, and the efficient collaboration with the Argenta regulatory team, we have successfully submitted our Marketing Authorisation Application (MAA) to the European Medicines Agency according to our planned schedule.

The highly favorable results of our multicenter pivotal Phase III study evaluating the efficacy of our cell therapy VBX-101 for canine osteoarthritis, combined with the robustness of our bioproduction platform, promise a successful outcome with regulatory authorities, veterinarians, dogs, and their owners.

Based in Lyon, Vetbiobank is a pharmaceutical establishment specializing in the development and biomanufacturing of Cell Therapies for veterinary medicine, focusing on the treatment of chronic inflammatory diseases in cats, dogs, and horses.